Advertisement
Advertisement


Information

Corrections to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

April 26, 2016

On April 26, 2016, the following updates were made to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (released March 1, 2016):

  • Emtricitabine, rilpivirine, tenofovir alafenamide, and tenofovir disoproxil fumarate were updated to include two newly released drugs and one updated formulation:
    • Odefsey: Recommendations and dosing for Odefsey were added to the Emtricitabine, Rilpivirine, and Tenofovir Alafenamide sections.
    • Descovy: Recommendations and dosing for Descovy were added to the Emtricitabine and Tenofovir Alafenamide sections.
    • Low-Strength Truvada: Dosing for low strength Truvada was added to the Tenofovir Disoproxil Fumarate and Emtricitabine sections.
  • Table 7 and Table 8 in the What to Start section were revised to correct information for tenofovir alafenamide plus emtricitabine containing regimens and to update fixed-dose combination availability with information for the newly released Odefsey and Descovy.


    Related Stories

    Read the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF)



    This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.
     

    No comments have been made.
     

    Add Your Comment:
    (Please note: Your name and comment will be public, and may even show up in
    Internet search results. Be careful when providing personal information! Before
    adding your comment, please read TheBody.com's Comment Policy.)

    Your Name:


    Your Location:

    (ex: San Francisco, CA)

    Your Comment:

    Characters remaining:

    Advertisement

    The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.